首页> 外国专利> Reversal of proinflammatory response by ligating the macrophage FcgammaRI receptor

Reversal of proinflammatory response by ligating the macrophage FcgammaRI receptor

机译:通过连接巨噬细胞FcgammaRI受体逆转促炎反应

摘要

Ligation of the Fc receptor type I (FcRI) on IL-10-producing cells leads to a selective upregulation of IL-10 production, which in turn induces a marked suppression of IL-12 biosynthesis by IL-12-producing cells, particularly macrophages. The ligation of the FcRI receptor thus downmodulates IL-12 production via a mechanism that is dependent on macrophage-derived IL-10. Agents for ligating FcRI comprise, for example, multivalent antibodies which bind the FcRI receptor, immune complexes comprising antibodies which contain the Fc region of IgG, and IgG multimers, preferably IgG dimers and trimers. The ligating agent may be administered to therapeutically inhibit proinflammatory immune responses. In particular, the ligating agent may be administered to treat or prevent endotoxic shock associated with bacterial endotoxemia, and to treating autoimmune disorders.
机译:产生IL-10的细胞上Fc受体I型(FcRI)的连接导致IL-10产生的选择性上调,进而诱导产生IL-12的细胞(特别是巨噬细胞)对IL-12生物合成的显着抑制。 。因此,FcRI受体的连接通过依赖于巨噬细胞的IL-10的机制下调IL-12的产生。用于连接FcRI的试剂包括,例如,结合FcRI受体的多价抗体,包含抗体的免疫复合物,所述抗体包含IgG的Fc区,以及IgG多聚体,优选IgG二聚体和三聚体。可以施用结扎剂以治疗性抑制促炎性免疫应答。特别地,可以给予连接剂以治疗或预防与细菌内毒素血症相关的内毒素性休克,并用于治疗自身免疫疾病。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号